422 related articles for article (PubMed ID: 27698003)
1. Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling.
Williams C; Lewsey JD; Mackay DF; Briggs AH
Med Decis Making; 2017 May; 37(4):427-439. PubMed ID: 27698003
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
Soini E; Hautala A; Poikonen E; Becker U; Kyttälä M; Martikainen J
Clin Ther; 2016 Apr; 38(4):889-904.e14. PubMed ID: 26970696
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial.
Williams C; Lewsey JD; Briggs AH; Mackay DF
Med Decis Making; 2017 May; 37(4):340-352. PubMed ID: 27281337
[TBL] [Abstract][Full Text] [Related]
5. Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes.
Smare C; Lakhdari K; Doan J; Posnett J; Johal S
Pharmacoeconomics; 2020 Jan; 38(1):97-108. PubMed ID: 31741315
[TBL] [Abstract][Full Text] [Related]
6. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
Casado LF; García Marco JA; Gilsanz F; González M; Ríos E; de la Serna J; Urbano A; Vicente V; Rubio-Terrés C; Castro AJ
Gac Sanit; 2011; 25(4):274-81. PubMed ID: 21664727
[TBL] [Abstract][Full Text] [Related]
7. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse.
Adena M; Houltram J; Mulligan SP; Todd C; Malanos G
Pharmacoeconomics; 2014 Feb; 32(2):193-207. PubMed ID: 24442832
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
Becker U; Briggs AH; Moreno SG; Ray JA; Ngo P; Samanta K
Value Health; 2016 Jun; 19(4):374-82. PubMed ID: 27325329
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
Walker S; Palmer S; Erhorn S; Brent S; Dyker A; Ferrie L; Horsley W; Macfarlane K; White S; Thomas S
Health Technol Assess; 2009 Jun; 13 Suppl 1():35-40. PubMed ID: 19567212
[TBL] [Abstract][Full Text] [Related]
10. A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology.
Cranmer H; Shields GE; Bullement A
J Med Econ; 2020 Oct; 23(10):1176-1185. PubMed ID: 32673128
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.
Goeree R; Villeneuve J; Goeree J; Penrod JR; Orsini L; Tahami Monfared AA
J Med Econ; 2016 Jun; 19(6):630-44. PubMed ID: 26850122
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands.
Blommestein HM; de Groot S; Aarts MJ; Vemer P; de Vries R; van Abeelen AF; Posthuma EF; Uyl-de Groot CA
Leuk Res; 2016 Nov; 50():37-45. PubMed ID: 27657652
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis.
Woods B; Hawkins N; Dunlop W; O'Toole A; Bramham-Jones S
Value Health; 2012; 15(5):759-70. PubMed ID: 22867787
[TBL] [Abstract][Full Text] [Related]
15. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia.
Liberato NL; Quaglini S; Barosi G
J Clin Oncol; 1997 Jul; 15(7):2673-82. PubMed ID: 9215840
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the flexible parametric survival model and Cox model in estimating Markov transition probabilities using real-world data.
Du X; Li M; Zhu P; Wang J; Hou L; Li J; Meng H; Zhou M; Zhu C
PLoS One; 2018; 13(8):e0200807. PubMed ID: 30133454
[TBL] [Abstract][Full Text] [Related]
18. A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme.
Connock M; Auguste P; Armoiry X
Eur J Health Econ; 2021 Feb; 22(1):89-100. PubMed ID: 33130929
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
